Observational Study
Copyright ©The Author(s) 2025.
World J Methodol. Mar 20, 2025; 15(1): 98482
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.98482
Figure 2
Figure 2 Reduction in macular vascular density in neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody disorder affected as well as unaffected eyes compared to controls. NMOSD: Neuromyelitis optica spectrum disorders; MOGAD: Myelin oligodendrocyte glycoprotein antibody disorder; MVD: Macular vascular density.